Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

BTIG starts Avita Medical at buy; PT $10

BTIG launched coverage of Avita Medical (NASDAQ:RCEL) with a “buy” rating and $10 price target. The stock closed at $8.32 on March 2. Avita’s RECELL system produces a suspension of spray-on-skin cells using a small...

March 3, 2020

Markets

Echelon ups Extendicare to buy; holds PT at $9

Echelon Wealth Partners upgraded Extendicare (TSX:EXE) to “buy” from “hold” but kept its price target at $9 after the company reported fourth quarter results. The stock closed at $7.85 (Canadian) on March 2. Analyst...

March 3, 2020

Markets

Mackie cuts Medexus Pharma to speculative buy; PT to $8.70 from $10.50

Mackie Research downgraded Medexus Pharmaceuticals (TSXV:MDP; OTCQB:PDDPF) to “speculative buy” from “buy” and lowered its price target to $8.70 (Canadian) from $10.50 after the company acquired Ixinity, a recombinant...

March 2, 2020

Markets

BTIG cuts IMV PT to $5 from $8

BTIG lowered its price target for IMV (NASDAQ, TSX:IMV) to $5 from $8, citing uncertainty about data from the company’s ongoing Phase 2 study of DPX-Survivac in patients with advanced recurrent ovarian cancer. The stock...

February 28, 2020

Markets

Dawson James cuts Adamis Pharma to neutral from buy; suspends PT

Dawson James Securities downgraded Adamis Pharmaceuticals (NASDAQ:ADMP) to “neutral” from “buy” and suspended its price target, citing a recent financing that “took us by surprise.” The stock closed at 57 cents on Feb...

February 27, 2020

Markets

WB starts Precision BioSciences at buy; fair value estimate $20

William Blair launched coverage of Precision BioSciences (NASDAQ:DTIL) with an “outperform” rating and fair value estimate of $20. The stock closed at $8.01 on Feb. 24. Precision has pioneered the development of its...

February 25, 2020

Markets

Roth resumes coverage of Altimmune at buy; PT $13

Roth Capital Partners resumed coverage of Altimmune (NASDSQ:ALT) with a “buy” rating and $13 price target. The stock closed at $1.76 on Feb. 21. “Altimmune represents a buying opportunity with its dual GLP-1: glucagon...

February 24, 2020

Markets

HCW cuts ReWalk Robotics PT to $3.50 from $9

H.C. Wainwright lowered its price target for ReWalk Robotics (NASDAQ:RWLK) to $3.50 from $9, reflecting dilution from a recent public offering. The stock closed at 81 cents on Feb. 20. As a result of the financing, the...

February 21, 2020

Markets

BTIG halves Endologix PT to $6 from $12

BTIG halved its price target for Endologix (NASDAQ:ELGX) to $6 from $12, but maintained its “buy” rating, saying the new target better reflects the current stock price, which closed at 89 cents on Feb. 19. Endologix...

February 20, 2020

Markets

WB cuts Tivity Health to market perform

William Blair downgraded Tivity Health (NASDAQ:TVTY) to “market perform” after fourth quarter results missed consensus estimates and Tivity announced the departure of several senior executives. The stock closed at $22...

February 20, 2020

Markets

Maxim ups Agile Therapeutics PT to $8 from $3

Maxim Group raised its price target for Agile Therapeutics (NASDAQ:AGRX) to $8 from $3 after the FDA approved the company’s weekly contraceptive patch, Twirla. The stock closed at $4.07 on Feb. 14. Agile shares...

February 18, 2020

Markets

Maxim ups Co-Diagnostics PT to $5 from $2

Maxim Group raised its price target for Co-Diagnostics (NASDAQ:CODX) to $5 from $2, citing the company’s rapid development of a coronavirus test. The stock closed at $3.32 on Feb. 14. Analyst Jason McCarthy writes that...

February 18, 2020

Markets

HCW halves Acasti Pharma PT to $3 from $6

H.C. Wainwright halved its price target for Acasti Pharma (NASDAQ:ACST) to $3 from $6 in light of the continued uncertainty around the company’s TRILOGY 1 and TRILOGY 2 trials. The stock closed at 57 cents on Feb. 14...

February 18, 2020

Markets

AGP ups Sensus Healthcare to buy; PT $6

Alliance Global Partners upgraded Sensus Healthcare (NASDAQ:SRTS) to “buy” from “neutral” with a price target of $6 after the company reported fourth quarter results. The stock closed at $4.62 on Feb. 13. Analyst Ben...

February 14, 2020

Markets

HCW cuts Pulse Biosciences to neutral; PT to $6 from $26

H.C. Wainwright downgraded Pulse Biosciences (NASDAQ:PLSE) to “neutral” from “buy” and slashed its price target to $6 from $26 after the FDA issued a “not substantially equivalent” (NSE) letter in response to the...

February 14, 2020

Markets

AGP starts Harvest Health at buy; PT $8

Alliance Global Partners launched coverage of Harvest Health & Recreation (CSE:HARV) with a “buy” rating and price target of $8 (Canadian). The stock closed at $3.57 on Feb. 10. “We believe the company is well...

February 11, 2020

Markets

AGP starts Curaleaf Holdings at buy; PT $14

Alliance Global Partners initiated coverage of Curaleaf Holdings (CSE:CURA) with a “buy” rating and price target of $14 (Canadian). The stock closed at $8.56 on Feb. 10. “We view Curaleaf as well-positioned to succeed...

February 11, 2020

Markets

SVB Leerink starts Abeona Therapeutics at OP; PT $6

SVB Leerink initiated coverage of Abeona Therapeutics (NASDAQ:ABEO) with an “outperform” rating and $6 price target. The stock closed at $2.51 on Feb. 7. “Abeona is a clinical stage gene therapy company with a realistic...

February 10, 2020

Markets

Maxim starts Heat Biologics at buy; PT $1

Maxim Group launched coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and price target of $1. The stock closed at 26 cents on Feb. 5. Heat is developing lead asset, ImPACT, a cell-based immune therapy for...

February 6, 2020

Markets

Maxim starts Armata Pharma at buy; PT $8

Maxim Group initiated coverage of Armata Pharmaceuticals (NYSE American:ARMP) with a “buy” rating and $8 price target. The stock closed at $3.71 on Feb. 5. Armata is developing phage therapies for the treatment of...

February 6, 2020

Markets

Piper Sandler starts Itamar Medical at OW; PT $22

Piper Sandler launched coverage of Itamar Medical (NASDAQ:ITMR) with an “overweight” rating and $22 price target. The stock closed at $16 on Feb. 4. Itamar makes home sleep testing products that are used to diagnose...

February 5, 2020

Markets

Brookline starts BioCeres Crop Solutions at buy; PT $13

Brookline Capital Markets initiated coverage of BioCeres Crop Solutions (NASDAQ:BIOX) with a “buy” rating and $13 price target. The stock closed at $4.95 on Feb. 4. BioCeres is the market leader in South America...

February 5, 2020

Subscribe